>>13421571

https://www.nytimes.com/2021/01/28/world/europe/vaccine-secret-contracts-prices.html

Early in the pandemic, the European Investment Bank, the lending arm of the European Union, provided a $100 million loan to the German company BioNTech, which partnered with Pfizer in producing a vaccine.

In addition to the interest on the loan, the European bank will receive up to $25 million in vaccine profits, according to a redacted version of the contract that BioNTech filed with securities regulators.

Wonder if there are more "deal deals" like this one with Pfizer associations? BioNTech did partner with Pfizer, so what else is underneath all those Euro redactions?

>>13421712 me

suits estimated 13B in November 2020…

https://www.theguardian.com/business/2020/nov/10/pfizer-and-biontech-could-make-13bn-from-coronavirus-vaccine

The US drugmaker Pfizer and the German biotech firm BioNTech stand to bring in nearly $13bn (£9.8bn) in global sales from their coronavirus vaccine next year, which will be evenly split between the two companies, according to analysts at the US investment bank Morgan Stanley.

and then a month later notch that up a bit to 32B

https://www.cnn.com/2020/12/11/business/pfizer-vaccine-covid-moderna-revenue/index.html

Wall Street analysts are projecting Pfizer and Moderna will generate $32 billion in Covid-19 vaccine revenue – next year alone.

>>13421743 me

https://theintercept.com/2021/03/18/covid-vaccine-price-pfizer-moderna/

PFIZER, one of the early global leaders in the vaccine race, is very clear about the enormous moneymaking opportunity they see in the vaccines. D’Amelio, the company’s CFO, spoke on a Zoom call last Thursday at the Barclays Global Healthcare Conference, to discuss the issue.

Carter Lewis Gould, an analyst with Barclays Bank, noted that Pfizer faced the particular challenges with “optics” but asked when the company could “pursue higher pricing down the road.”

The current pricing, said D’Amelio, is “clearly not being driven by what I’ll call normal market conditions, normal market forces,” but rather the “pandemic state that we’ve been in and the needs of governments to really secure doses from the various vaccine suppliers.” Once the pandemic ends, he continued, there will be “significant opportunity” for Pfizer.